<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910751</url>
  </required_header>
  <id_info>
    <org_study_id>POLESTAR_EMC2019</org_study_id>
    <nct_id>NCT03910751</nct_id>
  </id_info>
  <brief_title>POLESTAR Trial - An International Multi-center Early Discharge TAVI Program</brief_title>
  <acronym>POLESTAR</acronym>
  <official_title>Project to Look for Early Discharge in Patients Undergoing TAVI With ACURATE - An International Multi-center Early Discharge TAVI Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international multi-center prospective observational study to address safety and
      feasibility of an early discharge protocol in patients with symptomatic severe aortic
      stenosis who are eligible for transfemoral TAVI with the Boston Scientific ACURATE Neo Aortic
      Bioprosthesis transcatheter heart valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this International multi-center prospective observational study, 250 patients with severe
      symptomatic aortic stenosis (AS) and eligibility for transfemoral TAVI with ACURATE Neo
      Bioprosthesis, will be pre-procedurally selected for participation in an early discharge
      protocol in which patients are discharged within 48 hours after uncomplicated TAVI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause mortality, any stoke, life threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complication and valve-related dysfunction requiring repeat procedure at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause mortality, all stroke, all-cause re-hospitalization at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Composite of all-cause mortality, all stroke, all-cause re-hospitalization at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life threatening bleeding</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery obstruction requiring intervention</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complication</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve related dysfunction requiring repeat procedure</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause rehospitalization</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for valve-related symptoms or worsening congestive heart failure</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker implantation</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA heart failure class III or IV</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As measured by the EQ5D-5L quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As measured by the KCCQ quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical cost analysis</measure>
    <time_frame>30 days</time_frame>
    <description>Derived from length of stay on Intensive care unit and general ward</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis</intervention_name>
    <description>Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        250 patients with severe AS and selected for TF-TAVI with the ACURATE Neo valve and
        eligible for early discharge within 48 hours post TAVI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for ACURATE Neo valve implantation

          -  Patient agrees to follow-up duration

          -  Patient is able to understand and sign written informed consent

        Exclusion Criteria:

          -  BMI &gt; 35

          -  Pregnancy

        Cardiac

          -  Moderate to severely impaired left ventricular ejection fraction (LVEF &lt;35%)

          -  Mitral regurgitation ≥ moderate

          -  Pulmonary hypertension (sPAP &gt; 60mmHg)

          -  SYNTAX I score &gt;22

          -  Untreated high degree AV-block or RBBB

        Pulmonary

          -  COPD Gold ≥ 2

        Kidney function

          -  GFR &lt; 35ml/min

        Frailty

          -  Inappropriate social support and/or (familial) care

          -  Patient is walking aid dependent

        TAVI strategy

          -  Presence of severe peripheral artery disease

          -  Transfemoral approach not possible

        Follow up

          -  Inability to adhere to follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Van Mieghem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Van Mieghem, MD, PhD</last_name>
    <phone>0031(0)107035260</phone>
    <email>n.vanmieghem@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joris Ooms, MD</last_name>
    <phone>0031(0)107038896</phone>
    <email>j.f.w.ooms@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harindra Wijeysundera, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Wood, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Baan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Van der Kley, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Van Mieghem, MD</last_name>
      <phone>0031(0)107035260</phone>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utrecht University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter Stella, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Erik Nielsen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Rück, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nicolas van Mieghem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>Early discharge</keyword>
  <keyword>ACURATE Neo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

